Conflict of interest in the healthcare industry: Difference between revisions
m Dating maintenance tags: {{Update inline}} |
updating for cochrane taskexchange |
||
| Line 9: | Line 9: | ||
University projects which receive industry funding are more likely to produce research outcomes which favor their funders.<ref>{{cite journal|last1=Blumenthal|first1=D|last2=Gluck|first2=M|last3=Louis|first3=KS|last4=Stoto|first4=MA|last5=Wise|first5=D|title=University-industry research relationships in biotechnology: implications for the university.|journal=Science|date=13 June 1986|volume=232|issue=4756|pages=1361–6|pmid=3715452|doi=10.1126/science.3715452}}</ref> |
University projects which receive industry funding are more likely to produce research outcomes which favor their funders.<ref>{{cite journal|last1=Blumenthal|first1=D|last2=Gluck|first2=M|last3=Louis|first3=KS|last4=Stoto|first4=MA|last5=Wise|first5=D|title=University-industry research relationships in biotechnology: implications for the university.|journal=Science|date=13 June 1986|volume=232|issue=4756|pages=1361–6|pmid=3715452|doi=10.1126/science.3715452}}</ref> |
||
A |
A 2017 [[systematic review]] by the [[Cochrane Collaboration]] found that pharmaceutical and medical device industry sponsored studies are more often favorable to the sponsor's product compared with studies with other sources of sponsorship.<ref>{{cite journal|last1=Lundh|first1=A|last2=Lexchin|first2=J|last3=Mintzes|first3=B|last4=Schroll|first4=JB|last5=Bero|first5=L|title=Industry sponsorship and research outcome.|journal=The Cochrane database of systematic reviews|date=16 February 2017|volume=2|pages=MR000033|doi=10.1002/14651858.MR000033.pub3|pmid=28207928}}</ref> |
||
The trend toward treating [[clinical research]] as a business has coincided with a range of problems which are likely the result of business connections.<ref>{{cite journal|last1=Rettig|first1=RA|title=The industrialization of clinical research.|journal=Health affairs (Project Hope)|date=2000|volume=19|issue=2|pages=129–46|pmid=10718027|doi=10.1377/hlthaff.19.2.129}}</ref> |
The trend toward treating [[clinical research]] as a business has coincided with a range of problems which are likely the result of business connections.<ref>{{cite journal|last1=Rettig|first1=RA|title=The industrialization of clinical research.|journal=Health affairs (Project Hope)|date=2000|volume=19|issue=2|pages=129–46|pmid=10718027|doi=10.1377/hlthaff.19.2.129}}</ref> |
||
Revision as of 10:24, 7 August 2017
Conflict of interest in the health care industry occurs when the primary goal of protecting and increasing the health of patients comes into conflict with any other secondary goal, especially personal gain to healthcare professionals, and increasing revenue to a healthcare organization from selling health care products and services. The Public and private sectors of the medical-industrial complex have various conflicts of interest which are specific to these entities.
Trends
There is a lack of empirical evidence to describe the impact of conflict of interest in the health care industry.[1]
Business interests influence the direction of cancer research and the adoption of new practices in therapy.[2]
University projects which receive industry funding are more likely to produce research outcomes which favor their funders.[3]
A 2017 systematic review by the Cochrane Collaboration found that pharmaceutical and medical device industry sponsored studies are more often favorable to the sponsor's product compared with studies with other sources of sponsorship.[4]
The trend toward treating clinical research as a business has coincided with a range of problems which are likely the result of business connections.[5]
Funders seek and court scientists to author papers and lend their person reputations to add credibility to research findings.[6]
References
- ^ Malina, Debra; Rosenbaum, Lisa (2015). "Understanding Bias — The Case for Careful Study". New England Journal of Medicine. 372 (20): 1959–1963. doi:10.1056/NEJMms1502497. ISSN 0028-4793. PMID 25970055.
- ^ Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL (20 October 1999). "Evaluation of conflict of interest in economic analyses of new drugs used in oncology". JAMA. 282 (15): 1453–7. doi:10.1001/jama.282.15.1453. PMID 10535436.
- ^ Blumenthal, D; Gluck, M; Louis, KS; Stoto, MA; Wise, D (13 June 1986). "University-industry research relationships in biotechnology: implications for the university". Science. 232 (4756): 1361–6. doi:10.1126/science.3715452. PMID 3715452.
- ^ Lundh, A; Lexchin, J; Mintzes, B; Schroll, JB; Bero, L (16 February 2017). "Industry sponsorship and research outcome". The Cochrane database of systematic reviews. 2: MR000033. doi:10.1002/14651858.MR000033.pub3. PMID 28207928.
- ^ Rettig, RA (2000). "The industrialization of clinical research". Health affairs (Project Hope). 19 (2): 129–46. doi:10.1377/hlthaff.19.2.129. PMID 10718027.
- ^ "Sponsorship, Authorship, and Accountability". New England Journal of Medicine. 345 (11): 825–827. 2001. doi:10.1056/NEJMed010093. ISSN 0028-4793.
Further reading
- Rodwin, Marc A. (2011). Conflicts of Interest and the Future of Medicine: The United States, France, and Japan. Oxford University Press. ISBN 9780199792504. Retrieved 2015-05-14.
- Practice, Committee on Conflict of Interest in Medical Research, Education, and; Policy, Board on Health Sciences; Medicine, Institute of (2009-09-16). Conflict of Interest in Medical Research, Education, and Practice. National Academies Press. ISBN 9780309145442. Retrieved 2015-05-14.
{{cite book}}:|last2=has generic name (help)CS1 maint: multiple names: authors list (link)
